BFLABS CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,805 KRW | -11.09% |
|
-.--% | -54.90% |
| 04-08 | BFLABS Co.,LTD. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 02-23 | BFLABS Co.,LTD. announced that it expects to receive KRW 10 billion in funding | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 45,592 | 43,563 | 77,436 | 83,607 | 64,402 | 51,688 |
| Enterprise Value (EV) 1 | 60,047 | 94,243 | 67,102 | 98,976 | 68,728 | 54,167 |
| P/E ratio | -39.6 x | -3.02 x | -9.2 x | 66.5 x | -3.32 x | 583 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 1.19 x | 0.54 x | 0.68 x | 2.13 x | 2.27 x | 1.8 x |
| EV / Revenue | 1.57 x | 1.17 x | 0.59 x | 2.52 x | 2.42 x | 1.88 x |
| EV / EBITDA | -298 x | 69.4 x | 11.3 x | -28.7 x | -18.2 x | -24.9 x |
| EV / FCF | -4.25 x | 23.7 x | 7.41 x | -14.2 x | 6.38 x | -2.18 x |
| FCF Yield | -23.5% | 4.22% | 13.5% | -7.04% | 15.7% | -45.9% |
| Price to Book | 1.51 x | 2.12 x | 2.53 x | 1.65 x | 1.82 x | 1.19 x |
| Nbr of stocks (in thousands) | 2,047 | 3,293 | 4,693 | 6,557 | 7,073 | 8,310 |
| Reference price 2 | 22,275 | 13,230 | 16,500 | 12,750 | 9,105 | 6,220 |
| Announcement Date | 21/03/19 | 20/03/20 | 22/03/21 | 31/03/22 | 23/03/23 | 08/04/24 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 38,286 | 80,745 | 113,650 | 39,231 | 28,355 | 28,790 |
| EBITDA 1 | -201.2 | 1,358 | 5,946 | -3,444 | -3,784 | -2,179 |
| EBIT 1 | -998.3 | -1,433 | 2,077 | -5,516 | -5,161 | -3,261 |
| Operating Margin | -2.61% | -1.78% | 1.83% | -14.06% | -18.2% | -11.33% |
| Earnings before Tax (EBT) 1 | -1,296 | -11,620 | -1,557 | -7,952 | -20,159 | 46.56 |
| Net income 1 | -1,066 | -12,280 | -6,692 | 1,088 | -19,418 | 81.53 |
| Net margin | -2.78% | -15.21% | -5.89% | 2.77% | -68.48% | 0.28% |
| EPS 2 | -562.3 | -4,375 | -1,793 | 191.6 | -2,745 | 10.66 |
| Free Cash Flow 1 | -14,136 | 3,980 | 9,057 | -6,969 | 10,764 | -24,878 |
| FCF margin | -36.92% | 4.93% | 7.97% | -17.77% | 37.96% | -86.41% |
| FCF Conversion (EBITDA) | - | 293.12% | 152.31% | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 21/03/19 | 20/03/20 | 22/03/21 | 31/03/22 | 23/03/23 | 08/04/24 |
1KRW in Million2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 14,455 | 50,680 | - | 15,369 | 4,326 | 2,479 |
| Net Cash position 1 | - | - | 10,334 | - | - | - |
| Leverage (Debt/EBITDA) | -71.84 x | 37.33 x | - | -4.462 x | -1.143 x | -1.137 x |
| Free Cash Flow 1 | -14,136 | 3,980 | 9,057 | -6,969 | 10,764 | -24,878 |
| ROE (net income / shareholders' equity) | -3.51% | -24% | -3.5% | -9.4% | -44.6% | 0.21% |
| ROA (Net income/ Total Assets) | -1.13% | -0.75% | 0.7% | -2.46% | -4% | -3.18% |
| Assets 1 | 94,324 | 1,632,493 | -950,497 | -44,197 | 485,377 | -2,566 |
| Book Value Per Share 2 | 14,799 | 6,252 | 6,521 | 7,748 | 5,014 | 5,247 |
| Cash Flow per Share 2 | 1,179 | 6,413 | 10,579 | 1,562 | 376.0 | 567.0 |
| Capex 1 | 8,148 | 913 | 955 | 208 | 200 | 528 |
| Capex / Sales | 21.28% | 1.13% | 0.84% | 0.53% | 0.7% | 1.84% |
| Announcement Date | 21/03/19 | 20/03/20 | 22/03/21 | 31/03/22 | 23/03/23 | 08/04/24 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -54.90% | 17.92M | |
| -13.48% | 191B | |
| +1.53% | 167B | |
| +3.37% | 155B | |
| +8.31% | 103B | |
| +35.49% | 83.67B | |
| +11.32% | 82.06B | |
| -6.43% | 71.76B | |
| -18.66% | 54.05B | |
| -8.68% | 43.53B |
- Stock Market
- Equities
- A139050 Stock
- Financials BFLABS Co.,LTD.
